Literature DB >> 9256936

Homozygous delta 32 deletion of the CCR-5 chemokine receptor gene in an HIV-1-infected patient.

C Balotta1, P Bagnarelli, M Violin, A L Ridolfo, D Zhou, A Berlusconi, S Corvasce, M Corbellino, M Clementi, M Clerici, M Moroni, M Galli.   

Abstract

BACKGROUND: Recent research has found that entry of non-syncytium-inducing (NSI), monocyte-macrophage-tropic HIV-1 isolates requires binding to both CD4 and CCR5 receptors, and that delta 32/delta 32 homozygous individuals are protected against infection.
OBJECTIVE: To analyse the polymorphism of CCR-5 gene in HIV-1-infected and uninfected subjects. DESIGN AND METHODS: CCR-5 sequences were amplified by polymerase chain reaction (PCR) from DNA of peripheral blood mononuclear cells. Samples from 152 HIV-1-infected subjects and 122 uninfected controls were tested for the detection of the 32 base-pair deletion. HIV-1 phenotype was determined by viral isolation and MT-2 evaluation.
RESULTS: The wild-type/delta 32 heterozygous and delta 32/delta 32 homozygous conditions were represented in 10.7 and 0.8% of healthy controls and in 9.8 and 0.7% of HIV-1-infected subjects, respectively. Of note, the delta 32/delta 32 deletion of the CCR-5 gene was detected by PCR and sequencing confirmed in a patient with progressive infection harbouring a clade B virus with SI phenotype.
CONCLUSIONS: delta 32/delta 32 homozygosity for the CCR-5 gene does not confer absolute protection against HIV-1 infection, suggesting that either macrophage-tropic viral strains could use coreceptors other than CCR-5 or infect independently of the presence of a functional CCR-5 coreceptor. Alternatively, primary infection sustained by T-cell-tropic isolates, although exceptional, may occur.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9256936     DOI: 10.1097/00002030-199710000-00001

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  39 in total

1.  R5 human immunodeficiency virus type 1 (HIV-1) replicates more efficiently in primary CD4+ T-cell cultures than X4 HIV-1.

Authors:  Becky Schweighardt; Ann-Marie Roy; Duncan A Meiklejohn; Edward J Grace; Walter J Moretto; Jonas J Heymann; Douglas F Nixon
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

2.  CCR5Delta32 59537-G/A promoter polymorphism is associated with low translational efficiency and the loss of CCR5Delta32 protective effects.

Authors:  Qingwen Jin; Lokesh Agrawal; L Meyer; R Tubiana; Ioannis Theodorou; Ghalib Alkhatib
Journal:  J Virol       Date:  2007-12-19       Impact factor: 5.103

3.  Counterpoint: Cord blood stem cell therapy for acquired immune deficiency syndrome.

Authors:  Ghalib Alkhatib
Journal:  Stem Cells Dev       Date:  2009 Jan-Feb       Impact factor: 3.272

Review 4.  How does HIV-1 infect a susceptible human cell?: Current thinking.

Authors:  Ali A Al-Jabri
Journal:  J Sci Res Med Sci       Date:  2003-08

5.  A human immunodeficiency virus type 1 isolate from an infected person homozygous for CCR5Delta32 exhibits dual tropism by infecting macrophages and MT2 cells via CXCR4.

Authors:  Hassan M Naif; Anthony L Cunningham; Mohammed Alali; Shan Li; Najla Nasr; Marc M Buhler; Dominique Schols; Erik de Clercq; Graeme Stewart
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

6.  Exclusive and persistent use of the entry coreceptor CXCR4 by human immunodeficiency virus type 1 from a subject homozygous for CCR5 delta32.

Authors:  N L Michael; J A Nelson; V N KewalRamani; G Chang; S J O'Brien; J R Mascola; B Volsky; M Louder; G C White; D R Littman; R Swanstrom; T R O'Brien
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

Review 7.  HIV: cell binding and entry.

Authors:  Craig B Wilen; John C Tilton; Robert W Doms
Journal:  Cold Spring Harb Perspect Med       Date:  2012-08-01       Impact factor: 6.915

8.  Genetic and functional analysis of R5X4 human immunodeficiency virus type 1 envelope glycoproteins derived from two individuals homozygous for the CCR5delta32 allele.

Authors:  Lachlan Gray; Melissa J Churchill; Niamh Keane; Jasminka Sterjovski; Anne M Ellett; Damian F J Purcell; Pantelis Poumbourios; Chenda Kol; Bin Wang; Nitin K Saksena; Steven L Wesselingh; Patricia Price; Martyn French; Dana Gabuzda; Paul R Gorry
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

9.  Contribution of immunological and virological factors to extremely severe primary HIV type 1 infection.

Authors:  Judith Dalmau; Maria Carmen Puertas; Marta Azuara; Ana Mariño; Nicole Frahm; Beatriz Mothe; Nuria Izquierdo-Useros; Maria José Buzón; Roger Paredes; Lourdes Matas; Todd M Allen; Christian Brander; Carlos Rodrigo; Bonaventura Clotet; Javier Martinez-Picado
Journal:  Clin Infect Dis       Date:  2009-01-15       Impact factor: 9.079

10.  The effect of different immune responses on the evolution of virulent CXCR4-tropic HIV.

Authors:  D Wodarz; M A Nowak
Journal:  Proc Biol Sci       Date:  1998-11-22       Impact factor: 5.349

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.